Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Sci Rep ; 12(1): 14224, 2022 08 20.
Artículo en Inglés | MEDLINE | ID: mdl-35987984

RESUMEN

Sodium appetite is a motivational state involving homeostatic behavior, seeking the ingest of salty substances after sodium loss. There is a temporal dissociation between sodium depletion (SD) and the appearance of sodium appetite. However, the responsible mechanisms for this delay remain poorly elucidated. In the present study, we measured the temporal changes at two and 24 h after SD in the gene expression of key elements within excitatory, inhibitory, and sensory areas implicated in the signaling pathways involved in the onset of sodium appetite. In SD rats, we observed that the expression of critical components within the brain control circuit of sodium appetite, including Angiotensin-type-1 receptor (Agtr1a), Oxytocin-(OXT-NP)-neurophysin-I, and serotonergic-(5HT)-type-2c receptor (Htr2c) were modulated by SD, regardless of time. However, we observed reduced phosphorylation of mitogen-activated protein kinases (MAPK) at the paraventricular nucleus (PVN) and increased oxytocin receptor (Oxtr) mRNA expression at the anteroventral of the third ventricle area (AV3V), at two hours after SD, when sodium appetite is inapparent. At twenty-four hours after SD, when sodium appetite is released, we observed a reduction in the mRNA expression of the transient receptor potential channel 1gene (Trpv1) and Oxtr in the AV3V and the dorsal raphe nucleus, respectively. The results indicate that SD exerts a coordinated timing effect, promoting the appearance of sodium appetite through changes in MAPK activity and lower Trpv1 channel and Oxtr expression that trigger sodium consumption to reestablish the hydroelectrolytic homeostasis.


Asunto(s)
Apetito , Sodio en la Dieta , Animales , Apetito/fisiología , Biomarcadores , Oxitocina , ARN Mensajero/farmacología , Ratas , Receptor de Angiotensina Tipo 1/metabolismo , Sodio/metabolismo , Sodio en la Dieta/metabolismo
2.
Mol Cell Endocrinol ; 447: 98-105, 2017 05 15.
Artículo en Inglés | MEDLINE | ID: mdl-28254489

RESUMEN

This study aimed to define whether sex chromosome complement (SCC) may differentially modulate sex differences in relative gene expression of basal Agtr1a, Agtr2, and Mas1 receptors at fore/hindbrain nuclei and at medulla/cortical kidney. Samples were collected from gonadectomized male (XX and XY) and female (XX and XY) mice of the "four core genotypes" model. At brain level, a SCC effect at the area postrema was demonstrated. An increase in mRNA level of Agtr1a and Agtr1a/Agtr2 ratio in XY-SCC mice was associated with a decrease in Mas1 compared to XX-SCC mice. In the renal cortex, a SCC effect for Agtr2 and Mas1 was observed. Regardless of sex (male or female), XX-SCC mice expressed higher levels of mRNA Agtr2 and Mas1 than XY-SCC mice {F(1,12) = 6,126,p < 0.05; F(1,21) = 5,143,p < 0.05}. Furthermore, XX-female mice showed a significant increase in Mas1 expression compared to XY-female mice. These results reveal a SCC modulatory effect at central and kidney level on angiotensin receptor expression, with an enhancement of the vasodilatory arm in XX-mice and an increase in the vasoconstriction arm in XY-mice, which may underlie sex differences in the regulation of arterial pressure.


Asunto(s)
Proteínas Proto-Oncogénicas/metabolismo , Receptor de Angiotensina Tipo 1/metabolismo , Receptor de Angiotensina Tipo 2/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Caracteres Sexuales , Cromosomas Sexuales/metabolismo , Animales , Encéfalo/metabolismo , Femenino , Regulación de la Expresión Génica , Genotipo , Riñón/metabolismo , Masculino , Ratones , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptor de Angiotensina Tipo 1/genética , Receptor de Angiotensina Tipo 2/genética , Receptores Acoplados a Proteínas G/genética
3.
Hypertension ; 58(3): 505-11, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21810650

RESUMEN

To investigate whether sex chromosome complement modulates bradycardic baroreflex response and contributes to the angiotensin II-bradycardic baroreflex sex differences, we used the four core genotype mouse model in which the effect of gonadal sex and sex chromosome complement is dissociated, allowing comparisons of sexually dimorphic traits among XX and XY females, as well as in XX and XY males. In conscious gonadectomized (GDX) MF1 transgenic mice we evaluated baroreflex regulation of heart rate in response to changes in blood pressure evoked by phenylephrine (1 mg/mL), angiotensin II (100 µg/mL), and sodium nitroprusside (1 mg/mL). The administration of phenylephrine in GDX-XY females resulted in a significantly lower baroreflex response when compared with the other genotypes (in beats · min(-1) · mm Hg(-1) [slopes of regression lines for GDX-XY females -3.56±0.37 versus -6.06±0.38, -6.37±0.54 and -6.70±0.34 for GDX-XY male, GDX-XX female, and GDX-XX male mice, respectively]) {F(1,19)=9.63; P<0.01}. In addition, in both GDX-XY males and females, the angiotensin II-bradycardic baroreflex response was attenuated when compared with heart rate changes in GDX-XX male and female mice (in beats · min(-1) · mm Hg(-1) [slopes of regression lines: -2.83±0.28 versus -5.76±0.26 in GDX-XY and GDX-XX mice, respectively]) {F(1,19)=13.91; P<0.005}. In contrast, reflex tachycardic responses to sodium nitroprusside were comparable in all of the genotypes. These data support the hypothesis that sex chromosome complement modulates reflex inhibition of heart rate to phenylephrine and angiotensin II. Elucidating the foundational sources of sexually dimorphic traits in the regulation of baroreceptor reflex may enable the design of more appropriate sex-tailored therapeutic treatments in the future.


Asunto(s)
Barorreflejo/efectos de los fármacos , Bradicardia/fisiopatología , Aberraciones Cromosómicas Sexuales , Cromosoma X/genética , Cromosoma Y/genética , Angiotensina II/farmacología , Animales , Barorreflejo/genética , Barorreflejo/fisiología , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/genética , Presión Sanguínea/fisiología , Bradicardia/genética , Castración , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/genética , Frecuencia Cardíaca/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Ratones Transgénicos , Nitroprusiato/farmacología , Fenilefrina/farmacología , Factores Sexuales , Vasoconstrictores/farmacología , Vasodilatadores/farmacología
4.
Am J Physiol Regul Integr Comp Physiol ; 292(3): R1190-7, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17138727

RESUMEN

This study investigated the involvement of serotonergic mechanisms of the lateral parabrachial nucleus (LPBN) in the control of sodium (Na+) excretion, potassium (K+) excretion, and urinary volume in unanesthetized rats subjected to acute isotonic blood volume expansion (0.15 M NaCl, 2 ml/100 g of body wt over 1 min) or control rats. Plasma oxytocin (OT), vasopressin (VP), and atrial natriuretic peptide (ANP) levels were also determined in the same protocol. Male Wistar rats with stainless steel cannulas implanted bilaterally into the LPBN were used. In rats treated with vehicle in the LPBN, blood volume expansion increased urinary volume, Na+ and K+ excretion, and also plasma ANP and OT. Bilateral injections of serotonergic receptor antagonist methysergide (1 or 4 microg/200 etal) into the LPBN reduced the effects of blood volume expansion on increased Na+ and K+ excretion and urinary volume, while LPBN injections of serotonergic 5-HT(2a)/HT(2c) receptor agonist, 2.5-dimetoxi-4-iodoamphetamine hydrobromide (DOI; 1 or 5 microg/200 etal) enhanced the effects of blood volume expansion on Na+ and K+ excretion and urinary volume. Methysergide (4 microg) into the LPBN decreased the effects of blood volume expansion on plasma ANP and OT, while DOI (5 microg) increased them. The present results suggest the involvement of LPBN serotonergic mechanisms in the regulation of urinary sodium, potassium and water excretion, and hormonal responses to acute isotonic blood volume expansion.


Asunto(s)
Anfetaminas/farmacología , Volumen Sanguíneo , Metisergida/farmacología , Puente/fisiología , Receptores de Serotonina 5-HT2/fisiología , Cloruro de Sodio Dietético/farmacología , Anfetaminas/administración & dosificación , Animales , Factor Natriurético Atrial/sangre , Relación Dosis-Respuesta a Droga , Conducta de Ingestión de Líquido/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Metisergida/administración & dosificación , Microinyecciones , Oxitocina/sangre , Puente/efectos de los fármacos , Potasio/orina , Ratas , Ratas Wistar , Antagonistas de la Serotonina/administración & dosificación , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/administración & dosificación , Agonistas de Receptores de Serotonina/farmacología , Sodio/orina , Factores de Tiempo , Vasopresinas/sangre
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda